Research Adoption Risk Outranks Cost 1,220 to 686 in Market-Risk Entries as Long-Term Evidence Leads Named Research Gaps at 826 Across 3,581 Records

InnoDexis has published its latest Innovation Intelligence Report covering research gaps, risks and the future studies agenda, analyzing 3,581 research records, 96.3 percent of which state a gap, across 11 gap categories, 9 future-study categories and three risk families during the 1–29 September 2026 observation window. The report reveals that the risk research names most is that nobody adopts it: adoption or acceptance appears in 1,220 market-risk entries against 686 for cost and 140 for reimbursement, while the gaps research names are evidence gaps.

Key Findings

Evidence gaps dominate. Long-term follow-up or durability is named in 826 records, mechanism in 709, human or clinical validation in 503, replication or validation in 499 and larger or more diverse samples in 436, while scale-up or manufacturing is named in only 87 and cost or economics in 126.

Evidence gaps mark the least-ready work. Where replication, field testing, human validation or scale-up is the gap, High readiness is 3.8 to 4.6 percent, with 4.4 percent for human validation and 3.8 percent for replication, while where cost is the gap readiness is 20.6 percent, because cost becomes the question only near market.

Adoption is the leading market risk. It appears in 1,220 records against 686 for cost, 490 for funding and 488 for regulation, while technical-risk text names accuracy, bias or error in 601 records and durability in 499, reproducibility in only 124, and regulatory risk is mostly clinical approval at 777.

The future agenda is computational and cohort-based. Modelling and AI is proposed in 745 records and larger or longer cohorts in 723, against field and pilot tests in 346, clinical trials in 321 and scale-up in 284.

Gap profiles differ by country. US records most often name human or clinical validation, 20 percent, and mechanism, 24 percent, German records long-term durability, 25 percent, and integration, 9 percent, Chinese records long-term durability, 31 percent, and field testing, 21 percent, and ethical considerations appear in only 178 records, 5.0 percent.

Strategic Insight and Trend Analysis

The defining structural finding is that the evidence gap is the adoption gap. Adopters such as clinicians, utilities, regulators and buyers will not commit without long-term, replicated, human evidence, so the adoption risk research fears is largely the evidence gap it names. The same pattern runs through every family: therapeutics names human validation in 35 percent of records, energy long-term durability in 33 percent and field testing in 19 percent, and materials long-term durability in 35 percent.

The agenda proposed addresses part of the gap but not the part that convinces adopters. Modelling and larger cohorts are cheaper and faster than trials and pilots and suit a publicly funded research base, while field pilots, trials and scale-up, the work that convinces adopters, are planned less often, and records naming cost as a gap, 126, are the most ready. Research raises cost only when it is already close to market, so manufacturers and payers must ask the question for earlier work.

Stated risk predicts readiness strongly. Only 474 records, 13.2 percent, state an explicit risk level, 387 low, 27 moderate and 60 high, and low-risk records are 18.6 percent High readiness against 3.7 percent moderate and 1.7 percent high. Regulation means clinical approval, 777, followed by environmental and safety rules, 226, device and AI regulation, 194, and privacy, 110. Gap categories are multi-label keyword tags of analyst summaries, so totals can overlap, and readiness is analyst-assigned.

Global and Industry Implications

For corporates and R&D teams, bring manufacturing and economics into partnerships early, since research rarely asks about scale or cost, and filter research by future-studies plans that need industrial partners. Named follow-ups include the EASD long-term cohorts, KIT’s reliability testing of printed photonic connections and the STRABAG domain extension from FernUniversität Hagen. Offer field sites and accelerated-life testing where energy, materials and semiconductor gaps are durability.

For investors and capital allocators, evidence services are under-supplied relative to stated need, including trial and registry operators, AI validation test beds on the UKE trial model and field test sites for energy and materials. Due diligence should read the research-gaps field of any asset, since human-validation and replication gaps mark early assets.

For policymakers and national innovation bodies, evidence gaps are public goods, so funding long-term follow-up, replication and adoption studies raises the value of existing research. Named levers include long-term cohort and climatology infrastructure, such as the New York State Mesonet’s 30-year need, replication funds, and clear AI and device guidance. Ethical considerations should be stated, since only 5.0 percent of records do.

InnoDexis Statement

“The risk research names most is that nobody adopts it — and the gaps it names are the evidence adopters need, so whoever closes long-term, replicated, human and field evidence converts results into decisions,” noted InnoDexis in its latest intelligence report.

Conclusion

Because gap, risk and future-study fields are multi-label keyword tags of analyst summaries, readiness is analyst-assigned and one month supports no trend, the findings are cross-sectional. The signals to watch are whether proposed trials named in research records are registered, whether field pilot partners are announced for research technologies, whether replications of high-profile results are published, and whether regulators issue the AI and device guidance research names as a risk. The complete Research Gaps, Risks & Future Studies Agenda Report September 2026 is available to InnoDexis subscribers and enterprise clients.

About InnoDexis

InnoDexis is a real-time innovation intelligence platform connecting scientific discovery to commercial opportunity. Powered by InnoGraph, its proprietary innovation knowledge graph, the platform maps technologies across the entire lifecycle, from early-stage research (TRL 1) to market deployment (TRL 9), connecting researchers, institutions, startups, companies, products and emerging opportunities.

Covering 40+ specialised industry segments and 360 technology areas, InnoDexis delivers innovation tracking, research discovery, product and startup intelligence, investment insights, and AI-powered reports. Its mission is to bridge the gap between scientific discovery and real-world impact.

InnoDexis — From Lab to Market: Real-Time Innovation Intelligence.